Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance
NCT07269574 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2025-12-08
Summary
The goal of this retrospective observational study is to evaluate the relationship between different dietary patterns (specifically low-carbohydrate diets) and the prognosis of patients with high-grade serous ovarian cancer (HGSOC) receiving first-line PARP inhibitor (PARPi) maintenance therapy. The main questions it aims to answer are:
* Is there an association between dietary patterns and patients' Progression-Free Survival (PFS)?
* Is there an association between dietary patterns and Overall Survival (OS)? This is a multicenter, retrospective cohort study. Researchers will review electronic medical records from 14 tertiary hospitals in China to identify women who received first-line PARP inhibitor maintenance for advanced high-grade serous ovarian cancer between 2020 and 2025, and collect information on baseline characteristics, treatments and follow-up outcomes.
Researchers will compare patients with a "low-carbohydrate diet pattern" to those with a "regular/high-carbohydrate diet pattern" to see if there are differences in treatment outcomes and survival.
Participants will:
* Have their clinical, pathological, and treatment data collected from electronic medical records.
* Complete a retrospective Food Frequency Questionnaire (FFQ) via phone or clinic visit to recall their dietary habits during the maintenance treatment period.
* Optionally provide a blood sample for nutrition and metabolic analysis. (For participants at the main study center only) No experimental drugs or specific diets will be given in this study. All anti-cancer treatments are decided by the treating physicians as part of routine clinical care.
Conditions
- Ovarian Cancer
- Fallopian Tube Cancers
- Primary Peritoneal Carcinoma
- High-grade Serous Ovarian Cancer
Sponsors & Collaborators
-
West China Second University Hospital
collaborator OTHER -
Peking University People's Hospital
collaborator OTHER -
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
collaborator OTHER -
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
collaborator OTHER -
The Affiliated Hospital of Qingdao University
collaborator OTHER -
Qilu Hospital of Shandong University
collaborator OTHER -
Shanghai First Maternity and Infant Hospital
collaborator OTHER -
First Affiliated Hospital, Sun Yat-Sen University
collaborator OTHER -
The First Affiliated Hospital of Soochow University
collaborator OTHER -
Henan Provincial People's Hospital
collaborator OTHER -
The First Affiliated Hospital of Henan University of Science and Technology
collaborator OTHER -
Women's Hospital of Zhejiang University
collaborator UNKNOWN -
Sun Yat-sen University Cancer Centre
collaborator UNKNOWN -
Tongji Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-11-27
- Primary Completion
- 2026-11-30
- Completion
- 2026-12-31
More Related Trials
-
Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
NCT05669768 ·Status: UNKNOWN ·Phase: PHASE2
-
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
NCT06954584 ·Status: RECRUITING ·Phase: PHASE3
-
Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer
NCT06572735 ·Status: RECRUITING
-
A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib
NCT06037213 ·Status: UNKNOWN
-
New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer
NCT06120309 ·Status: ENROLLING_BY_INVITATION
-
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial
NCT05607329 ·Status: RECRUITING ·Phase: NA
-
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
NCT03042897 ·Status: WITHDRAWN ·Phase: NA
-
Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors
NCT04917744 ·Status: COMPLETED
-
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
First-line Olaparib Combined With Bevacizumab Maintenance Therapy
NCT05440578 ·Status: UNKNOWN
-
Fertility Preservation and Pregnancy and Offspring Health Outcomes in Female Cancer
NCT06360471 ·Status: RECRUITING
-
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00719303 ·Status: UNKNOWN ·Phase: PHASE3
-
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
NCT06063070 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
NCT01372787 ·Status: UNKNOWN
-
Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients
NCT06622798 ·Status: RECRUITING
-
Short-term Fasting Compared to Free Diet on Ovarian Cancer Patients
NCT07039331 ·Status: RECRUITING ·Phase: NA
-
Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer
NCT04986371 ·Status: UNKNOWN
-
Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer
NCT06216496 ·Status: RECRUITING ·Phase: NA
-
Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study
NCT05734911 ·Status: COMPLETED
-
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
NCT01652794 ·Status: COMPLETED ·Phase: PHASE1
-
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
NCT02065687 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR Inhibitors
NCT05640024 ·Status: RECRUITING
-
Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients
NCT05044091 ·Status: UNKNOWN
-
Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
NCT06785077 ·Status: RECRUITING ·Phase: NA
-
Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers
NCT02412124 ·Status: TERMINATED ·Phase: NA